US Patent

US7989448 — Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Method of Use · Assigned to Rigel Pharmaceuticals Inc · Expires 2026-06-12 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects prodrugs of 2,4-pyrimidinediamine compounds and their uses to inhibit cellular degranulation and treat associated diseases.

USPTO Abstract

The present disclosure provides compounds of the following formula, and methods of using the compounds to inhibit cellular degranulation and to treat diseases associated therewith.

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2294`	—	fostamatinib-disodium
`U-2294`	—	fostamatinib-disodium

Patent Metadata

Patent number: US7989448
Jurisdiction: US
Classification: Method of Use
Expires: 2026-06-12
Drug substance claim: Yes
Drug product claim: No
Assignee: Rigel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.